Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 12NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × ridaforolimus × Clear all
NCT00770185 2023-08-04

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Canadian Cancer Trials Group

Phase 2 Completed
35 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡